Pharnext to Present at the H.C. Wainwright Annual Global Life Sciences Conference
March 29 2018 - 11:45AM
Business Wire
Regulatory News:
Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA),
a biopharmaceutical company pioneering a new approach to the
development of innovative drugs based on the combination and
repositioning of known drugs, today announced that company
management will present a corporate overview at the H.C. Wainwright
Annual Global Life Sciences Conference.
The presentation will take place as follows:
- Date: Tuesday, April 10th,
2018
- Time: 2:10 pm CEST
- Venue: Le Meridien Beach Plaza
Hotel in Monte Carlo, Monaco
Pharnext’s first-in-class PLEODRUG™, PXT3003, is currently in an
international Phase 3 trial for the treatment of the rare disease
Charcot-Marie-Tooth disease type 1A. The results of this trial are
expected before the end of 2018.
If you are interested in meeting the Pharnext management team
during this event or if you need more information about Pharnext's
participation, please send an email to investors@pharnext.com
About PharnextPharnext is an advanced clinical-stage
biopharmaceutical company developing novel therapeutics for orphan
and common neurodegenerative diseases that currently lack curative
and/or disease-modifying treatments. Pharnext has two lead products
in clinical development. PXT3003 is currently in an international
Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type
1A and benefits from orphan drug status in Europe and the United
States. The results of this trial are expected in the second half
of 2018. PXT864 has generated positive Phase 2 results in
Alzheimer’s disease. Pharnext has developed a new drug discovery
paradigm: PLEOTHERAPY™. The Company identifies and develops
synergic combinations of repositioned drugs at new optimal lower
doses. These PLEODRUG™ offer several key advantages: efficacy,
safety and intellectual property, including several product or
composition of matter patents already granted. The Company was
founded by renowned scientists and entrepreneurs including
Professor Daniel Cohen, a pioneer in modern genomics and is
supported by a world-class scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris
(ISIN code: FR0011191287).For more information, visit
www.pharnext.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180329005796/en/
PharnextXavier Paoli, +33 (0)1 41 09 22 30Chief
Commercial Officercontact@pharnext.comorInvestor Relations
(Europe)MC Services AGAnne Hennecke, +49 211 529252
22anne.hennecke@mc-services.euorInvestor Relations
(U.S.)Stern Investor Relations, Inc.Matthew Shinseki, +1 212
362 1200matthew@sternir.comorFinancial Communication
(France)ActifinStéphane Ruiz, +33 (0)1 56 88 11
15sruiz@actifin.frorMedia Relations (Europe)ALIZE RPCaroline
Carmagnol / Aurore Gangloff+33 (0)1 44 54 36
64pharnext@alizerp.comorMedia Relations
(U.S.)RooneyPartnersMarion Janic, +1 212 223
4017mjanic@rooneyco.com
Pharnext (EU:ALPHA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pharnext (EU:ALPHA)
Historical Stock Chart
From Apr 2023 to Apr 2024